Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development
with Boehringer Ingelheim for the once-daily, oral treatment of cancer. Afatinib …

Lung cancer is the leading cause of cancer-related death worldwide with a 5-year survival
rate of less than 15%, despite significant advances in both diagnostic and therapeutic …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has
improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung …

Introduction The main objective of the current post hoc analysis was to compare patient-
reported outcomes between crizotinib (N= 172) and chemotherapy subgroups (pemetrexed …

Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …

Background Health state utility values (HSUVs) are an important input to economic
evaluations and the choice of HSUV can affect the estimate of relative cost-effectiveness …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Chronic pain has been widely recognized as a major public health problem that impacts
multiple aspects of patient quality of life. Unfortunately, chronic pain is often resistant to …